drug_type
RELEVANT_DRUG
intervention_type
radioimmunotherapy (radiolabeled monoclonal antibody)
drug_description
Radiolabeled anti-CD33 monoclonal antibody (Actimab-A) that delivers Actinium-225 alpha particles to CD33-expressing leukemic cells, causing DNA double-strand breaks and cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lintuzumab
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD33 monoclonal antibody (lintuzumab) conjugated to the alpha-emitter Actinium-225 targets CD33-expressing leukemic cells; localized high–linear energy transfer alpha radiation induces clustered DNA double-strand breaks, leading to cytotoxicity/apoptosis with limited tissue penetration.
drug_name
Lintuzumab-Ac225
nct_id_drug_ref
NCT03932318